Added to YB: 2025-12-10
Pitch date: 2025-12-08
NOVO-B.CO [bullish]
Novo Nordisk A/S
+6.94%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 300.30
Price Target
450.00 (+40%)
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
turnaround
Novo Nordisk ($NVO): Bridging the Valley
NOVO-B.CO: Trading 12.5x forward P/E vs Lilly's 34.6x despite leading GLP-1 franchise. 2026 'air pocket' from patent cliffs & pricing pressure (-2% rev, -7% EPS per Berenberg) creates opportunity. CagriSema 'Zepbound killer' filing early 2026, oral sema approval 2025. 450 DKK target.
Read full article (4 min)